Now Accepting New Participants
What's Involved?
- a startup visit, which includes a 3.5 hour visit and 3 follow-up visits within 24 hours
- take 2 capsules each day for 2 months
- final visit for a final blood draw
Who Can Join?
- healthy women, age 23-42, inclusive
- must be experiencing fatigue, poor concentration, or other signs of decreased energy
- local to Huntsville AL
Will I Be Paid?
Yes! You will be paid up to $300 for completing the study.
You will receive $100 for the first day, $50 after the 28-day checkin, and the final $150 after the final visit.
Learn More
Getting Started
To get started, click the buttons on this page to request access to a screening survey. A researcher will review your health history to ensure the study is a good fit for you.
If you are invited to participate, you will receive a link to schedule your site visit.
During the Study
Your startup visit will be the longest visit. It involves arriving fasted early in the morning (appointments are scheduled between 7AM and 8AM), providing a baseline blood draw, taking the first mineral supplement, then providing a blood draw again after 30 minutes, 1 hour, and 3 hours. At this time, we will feed you and you will be allowed to leave.
You will need to return twice more on the first day (at hour 6 and 12), then once on the following morning for 15 minute visits. Then you will take the mineral supplement every day from home for two menstrual cycles (approx 56 days). You will return on the final day for one last blood draw.
Your Benefits
We will send you up to $300 for participating. You will also receive your 2-month supply of the supplement for free. (There are no placebos in this study; everyone receives a real supplement!)
During the study, our team is available to you 24/7.
Interested in the results? Once the study is complete, a private zoom invitation will be sent to all study participants with an overview of the findings.
Disclosures: The purpose of this study is to evaluate the absorption rates of an iron supplement. This clinical trial protocol has been evaluated and approved by an independent third-party ethical review board which is accredited by the US Department of Health and Human Services' Office of Human Research Protections (HHS-OHRP). It is conducted in compliance with the Declaration of Helsinki, the Belmont Report, the regulations outlined in 45 CFR 46, and ICH GCP E6 (R2). The protocol is also registered in a World Health Organization (WHO) approved clinical trial registry.